Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
Open Access
- 1 October 2022
- journal article
- editorial
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 28, e938532-1-e938532-3
Abstract
One of the most recently described clinical associations with SARS-CoV-2 infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid). On 24 May 2022, the US Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory update for patients, healthcare providers, and public health departments on COVID-19 rebound or recurrence of COVID-19. However, population data from the US showed no significant differences in the risk of developing rebound COVID-19 between patients treated with Paxlovid and Molnupiravir. The mechanisms of rebound COVID-19 remain unclear but may involve the development of resistance to the antiviral drug, impaired immunity to the virus, or insufficient drug dosing. A further explanation may be the persistence of a high viral load of SARS-CoV-2 in individuals who are no longer symptomatic. This Editorial aims to provide an update on what is known about rebound COVID-19 and the current public health implications.Keywords
This publication has 11 references indexed in Scilit:
- From Positive to Negative to Positive Again—The Mystery of Why COVID-19 Rebounds in Some Patients Who Take PaxlovidJAMA, 2022
- Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2022
- COVID-19 2022 update: transition of the pandemic to the endemic phaseHuman Genomics, 2022
- SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategiesInternational Reviews of Immunology, 2022
- The changing epidemiology of SARS-CoV-2Science, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized PatientsMedical Science Monitor, 2022
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021
- Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 InfectionJAMA Network Open, 2021
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020